CD8 TIL cell therapy - Aventis Gencell
Latest Information Update: 09 Jul 2002
At a glance
- Originator Aventis Gencell
- Class Antineoplastics; Immunotherapies; Tumour infiltrating lymphocyte therapies
- Mechanism of Action Lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Graft-versus-host disease; Renal cancer